TAMOXIFEN AND RELATED-COMPOUNDS DECREASE MEMBRANE FLUIDITY IN LIPOSOMES - MECHANISM FOR THE ANTIOXIDANT ACTION OF TAMOXIFEN AND RELEVANCE TO ITS ANTICANCER AND CARDIOPROTECTIVE ACTIONS

被引：107

作者：

WISEMAN, H ^{[1
]}

QUINN, P ^{[1
]}

HALLIWELL, B ^{[1
]}

机构：

[1] UNIV LONDON,KINGS COLL,DIV LIFE SCI,LONDON W8 7AH,ENGLAND

来源：

FEBS LETTERS | 1993年 / 330卷 / 01期

关键词：

MEMBRANE FLUIDITY; TAMOXIFEN; ANTIOXIDANT ACTION; LIPOSOMAL LIPID PEROXIDATION; ANTICANCER ACTION; CARDIOPROTECTANT;

D O I：

10.1016/0014-5793(93)80918-K

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Tamoxifen and related compounds decrease membrane fluidity in ox-brain phospholipid liposomes: their order of effectiveness is, 4-hydroxytamoxifen > 17 beta-oestradiol > tamoxifen > cis-tamoxifen > N-desmethyltamoxifen > cholesterol. A good positive correlation was demonstrated between the decrease in membrane fluidity by these compounds and their antioxidant ability as inhibitors of liposomal and microsomal lipid peroxidation (correlation coefficient, r = 0.99, P < 0.001, in both cases). The ability of tamoxifen to decrease membrane fluidity is suggested to be the mechanism of its antioxidant action and is discussed in relation to its anticancer and cardioprotective actions.

引用

页码：53 / 56

页数：4

共 30 条

[1] RESULTS OF THE CANCER-RESEARCH CAMPAIGN ADJUVANT TRIAL FOR PERIOPERATIVE CYCLOPHOSPHAMIDE AND LONG-TERM TAMOXIFEN IN EARLY BREAST-CANCER REPORTED AT THE 10TH YEAR OF FOLLOW-UP
BAUM, M
HOUGHTON, J
RILEY, D
MACINTYRE, J
BERSTOCK, D
MCKINNA, A
JACKSON, I
SAINSBURY, JRC
WILSON, A
WHEELER, T
DOBBS, J
REES, G
POWLES, T
RUBENS, R
HAYBRITTLE, J
MCPHERSON, K
HOUGHTON, J
[J]. ACTA ONCOLOGICA, 1992, 31 (02) : 251 - 257
[2] BUTTA A, 1992, CANCER RES, V52, P4261
[3] REDUCTION OF THE MEMBRANE FLUIDITY OF HUMAN BREAST-CANCER CELLS BY TAMOXIFEN AND 17-BETA-ESTRADIOL
CLARKE, R
VANDENBERG, HW
MURPHY, RF
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (21) : 1702 - 1705
[4] CLINICAL AND RADIOGRAPHIC RESPONSE IN A MINORITY OF PATIENTS WITH RECURRENT MALIGNANT GLIOMAS TREATED WITH HIGH-DOSE TAMOXIFEN
COULDWELL, WT
WEISS, MH
DEGIORGIO, CM
WEINER, LP
HINTON, DR
EHRESMANN, GR
CONTI, PS
APUZZO, MLJ
KORNBLITH, P
DETRIBOLET, N
TAOA, M
LEVIN, VA
OLDFIELD, EH
[J]. NEUROSURGERY, 1993, 32 (03) : 485 - 490
[5] LONG-TERM EFFECTS OF TAMOXIFEN ON BLOOD LIPID VALUES IN BREAST-CANCER
DEWAR, JA
HOROBIN, JM
PREECE, PE
TAVENDALE, R
TUNSTALLPEDOE, H
WOOD, RAB
[J]. BRITISH MEDICAL JOURNAL, 1992, 305 (6847) : 225 - 226
[6] THE CYCLIC AMP-MEDIATED STIMULATION OF CELL-PROLIFERATION
DUMONT, JE
JAUNIAUX, JC
ROGER, PP
[J]. TRENDS IN BIOCHEMICAL SCIENCES, 1989, 14 (02) : 67 - 71
[7] PROSPECTIVE CONTROLLED TRIAL WITH ANTIESTROGEN DRUG TAMOXIFEN IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR-CARCINOMA
FARINATI, F
DEMARIA, N
FORNASIERO, A
SALVAGNINI, M
FAGIUOLI, S
CHIARAMONTE, M
NACCARATO, R
[J]. DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (05) : 659 - 662
[8] GUTTERIDGE JMC, 1978, RES COMMUN CHEM PATH, V22, P563
[9] HAMILTON C, 1992, INTRO NEW TREATMENTS, P315
[10] REGULATION OF ADENYLATE-CYCLASE (EC 4.6.1.1) ACTIVITY BY ITS LIPID ENVIRONMENT
HOUSLAY, MD
[J]. PROCEEDINGS OF THE NUTRITION SOCIETY, 1985, 44 (02) : 157 - 165

← 1 2 3 →